MX347191B - Inhibidores de aminopirimidina cinasa. - Google Patents
Inhibidores de aminopirimidina cinasa.Info
- Publication number
- MX347191B MX347191B MX2014005052A MX2014005052A MX347191B MX 347191 B MX347191 B MX 347191B MX 2014005052 A MX2014005052 A MX 2014005052A MX 2014005052 A MX2014005052 A MX 2014005052A MX 347191 B MX347191 B MX 347191B
- Authority
- MX
- Mexico
- Prior art keywords
- pathway
- compounds
- kinase inhibitors
- ckiyl
- ckiy3
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 230000037361 pathway Effects 0.000 abstract 8
- 108091054872 CK2 family Proteins 0.000 abstract 2
- 230000004163 JAK-STAT signaling pathway Effects 0.000 abstract 2
- 101100297651 Mus musculus Pim2 gene Proteins 0.000 abstract 2
- 101150054691 PIM3 gene Proteins 0.000 abstract 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 abstract 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 abstract 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 2
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- -1 aminopyrimidine compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001766 physiological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161555617P | 2011-11-04 | 2011-11-04 | |
| PCT/US2012/061597 WO2013066684A1 (en) | 2011-11-04 | 2012-10-24 | Aminopyrimidine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014005052A MX2014005052A (es) | 2015-03-19 |
| MX347191B true MX347191B (es) | 2017-04-19 |
Family
ID=47116510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014005052A MX347191B (es) | 2011-11-04 | 2012-10-24 | Inhibidores de aminopirimidina cinasa. |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8927525B2 (enExample) |
| EP (1) | EP2776432B1 (enExample) |
| JP (1) | JP6215832B2 (enExample) |
| KR (1) | KR101990605B1 (enExample) |
| CN (1) | CN104011046B (enExample) |
| AU (1) | AU2012332931B2 (enExample) |
| BR (1) | BR112014010563B1 (enExample) |
| CA (1) | CA2853454C (enExample) |
| ES (1) | ES2629690T3 (enExample) |
| IL (1) | IL232234A0 (enExample) |
| MX (1) | MX347191B (enExample) |
| PL (1) | PL2776432T3 (enExample) |
| RU (1) | RU2674017C2 (enExample) |
| WO (1) | WO2013066684A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102884062B (zh) * | 2009-12-23 | 2016-08-03 | 嘉世高制药公司 | 氨基嘧啶激酶抑制剂 |
| AU2012245344B2 (en) * | 2011-04-22 | 2017-11-09 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| CN104011046B (zh) | 2011-11-04 | 2017-05-03 | 嘉世高制药公司 | 氨基嘧啶激酶抑制剂 |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| EP3036238A1 (en) | 2013-08-23 | 2016-06-29 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| JP7083309B2 (ja) | 2015-08-04 | 2022-06-10 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム エルティーディー． | ピラゾールピリミジン誘導体及びその使用 |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US11072599B2 (en) | 2017-02-01 | 2021-07-27 | Biotheryx, Inc. | Pyrazole compounds and uses thereof |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| KR20220081359A (ko) | 2019-10-09 | 2022-06-15 | 바이엘 악티엔게젤샤프트 | 살충제로서의 신규 헤테로아릴-트리아졸 화합물 |
| WO2025132870A1 (en) * | 2023-12-21 | 2025-06-26 | Glaxosmithkline Intellectual Property (No.4) Limited | Chemical compounds and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW245716B (enExample) | 1992-12-28 | 1995-04-21 | Takeda Pharm Industry Co | |
| IL113112A (en) * | 1994-03-28 | 2000-06-01 | Nissan Chemical Ind Ltd | Pyridine substituted thiazolidinediones and pharmaceutical compositions comprising them |
| US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
| AU712802B2 (en) | 1994-10-20 | 1999-11-18 | Nippon Chemiphar Co. Ltd. | Quinoline derivatives |
| BRPI0512261A (pt) | 2004-06-17 | 2008-02-26 | Wyeth Corp | antagonistas de receptor de hormÈnio liberador de gonadotropina |
| PL1786812T3 (pl) * | 2004-09-03 | 2012-04-30 | Merck Serono Sa | Pirydynometylenoazolidynony i ich zastosowanie jako inhibitorów fosfoinozytydów |
| US20090042773A1 (en) | 2004-10-12 | 2009-02-12 | Reinhard Wetzker | P13 kinase gamma inhibitors for the treatment of anaemia |
| EP1916249A1 (en) | 2006-10-10 | 2008-04-30 | LEK Pharmaceuticals D.D. | 3-(benzo[d][1,3]dioxol-5-ylmethyl)-4-(thio)oxo-2-(thio)oxo-azolidin-5-ylidene derivatives as antibacterial agents |
| WO2009064486A2 (en) * | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| US8252823B2 (en) | 2008-01-28 | 2012-08-28 | New York University | Oxazole and thiazole compounds as beta-catenin modulators and uses thereof |
| MX2011004553A (es) | 2008-10-29 | 2011-07-20 | Sirtris Pharmaceuticals Inc | Piridina, piridina biciclica y analogos relacionados como moduladores de sirtuina. |
| US20100331315A1 (en) * | 2009-06-18 | 2010-12-30 | Mustapha Haddach | Rhodanines and related heterocycles as kinase inhibitors |
| CN102884062B (zh) | 2009-12-23 | 2016-08-03 | 嘉世高制药公司 | 氨基嘧啶激酶抑制剂 |
| AU2012245344B2 (en) | 2011-04-22 | 2017-11-09 | Jasco Pharmaceuticals, LLC | Aminopyrimidine kinase inhibitors |
| CN104011046B (zh) | 2011-11-04 | 2017-05-03 | 嘉世高制药公司 | 氨基嘧啶激酶抑制剂 |
-
2012
- 2012-10-24 CN CN201280053781.XA patent/CN104011046B/zh not_active Expired - Fee Related
- 2012-10-24 EP EP12780393.0A patent/EP2776432B1/en active Active
- 2012-10-24 MX MX2014005052A patent/MX347191B/es active IP Right Grant
- 2012-10-24 JP JP2014539984A patent/JP6215832B2/ja not_active Expired - Fee Related
- 2012-10-24 US US13/659,343 patent/US8927525B2/en active Active
- 2012-10-24 CA CA2853454A patent/CA2853454C/en active Active
- 2012-10-24 RU RU2014122344A patent/RU2674017C2/ru active
- 2012-10-24 PL PL12780393T patent/PL2776432T3/pl unknown
- 2012-10-24 BR BR112014010563-4A patent/BR112014010563B1/pt not_active IP Right Cessation
- 2012-10-24 KR KR1020147014718A patent/KR101990605B1/ko not_active Expired - Fee Related
- 2012-10-24 AU AU2012332931A patent/AU2012332931B2/en active Active
- 2012-10-24 ES ES12780393.0T patent/ES2629690T3/es active Active
- 2012-10-24 WO PCT/US2012/061597 patent/WO2013066684A1/en not_active Ceased
-
2014
- 2014-04-24 IL IL232234A patent/IL232234A0/en active IP Right Grant
- 2014-12-19 US US14/577,079 patent/US9629840B2/en active Active
-
2016
- 2016-12-09 US US15/374,013 patent/US10336743B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140098105A (ko) | 2014-08-07 |
| MX2014005052A (es) | 2015-03-19 |
| EP2776432B1 (en) | 2017-03-29 |
| BR112014010563B1 (pt) | 2021-01-12 |
| US20150202205A1 (en) | 2015-07-23 |
| CN104011046B (zh) | 2017-05-03 |
| CA2853454C (en) | 2020-01-21 |
| JP2015501782A (ja) | 2015-01-19 |
| RU2014122344A (ru) | 2015-12-10 |
| BR112014010563A2 (pt) | 2017-04-25 |
| JP6215832B2 (ja) | 2017-10-18 |
| AU2012332931A1 (en) | 2014-06-12 |
| RU2674017C2 (ru) | 2018-12-04 |
| ES2629690T3 (es) | 2017-08-14 |
| CA2853454A1 (en) | 2013-05-10 |
| US20130310342A1 (en) | 2013-11-21 |
| CN104011046A (zh) | 2014-08-27 |
| US10336743B2 (en) | 2019-07-02 |
| IL232234A0 (en) | 2014-06-30 |
| EP2776432A1 (en) | 2014-09-17 |
| WO2013066684A1 (en) | 2013-05-10 |
| PL2776432T3 (pl) | 2017-10-31 |
| US20170247367A1 (en) | 2017-08-31 |
| US8927525B2 (en) | 2015-01-06 |
| KR101990605B1 (ko) | 2019-06-18 |
| US9629840B2 (en) | 2017-04-25 |
| AU2012332931B2 (en) | 2017-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014005052A (es) | Inhibidores de aminopirimidina cinasa. | |
| WO2012145617A3 (en) | Aminopyrimidine kinase inhibitors | |
| NZ608116A (en) | Triazine-oxadiazoles | |
| EA201201192A1 (ru) | Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций | |
| PH12013501618A1 (en) | New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors | |
| EA201200618A1 (ru) | Производные хроменона с антиопухолевой активностью | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MX2012012571A (es) | Dicarboxamidas de ciclopropilo y analogos que muestran actividades anti-cancerosas y anti-proliferativas. | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| MD4590B1 (ro) | Derivaţi macrociclici pentru tratamentul bolilor proliferative | |
| IL211825A (en) | Compounds based on pyridine and pyrimidine for use as wnt signal transducer inhibitors, pharmaceutical formulations containing such compounds and used as drugs for the treatment and / or cancer prevention | |
| TW200806300A (en) | New therapeutic combinations for the treatment of depression | |
| MX345238B (es) | (aralquilamino y heteroarilalquilamino alfa-substituidos)pirimidin ilo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas. | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| PH12013500007A1 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| JO3434B1 (ar) | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| MX355015B (es) | Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal. | |
| WO2011103289A3 (en) | Imidazole-2, 4-dione inhibitors of casein kinase 1 | |
| HK1201839A1 (en) | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an o-containing group as vanilloid receptor ligands | |
| TN2014000528A1 (en) | Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease | |
| NZ707832A (en) | 2-pyridone compound | |
| EP2402342A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES | |
| PH12015500282A1 (en) | N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |